RxDoctor Payments Data

Chitra Kumar, MD

Hematology & Oncology · West New York, NJNPI 1083663496

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,124 of the $4,941 with a category attached, or 83.5%. It is spread thinly across 49 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,256, 5.2 times the $242 reported in 2019.

$4,941in general payments, 2019–2025

Across 276 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$554
  • Johnson & Johnson$480
  • Daiichi Sankyo Inc.$308
  • Amgen$268
  • Astellas Pharma US Inc$254
  • AstraZeneca$226
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$4,12483%
  • Education$81717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,941 in reported general payments places this provider in the 60th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$128,430
Medicare patients
57
Services billed
27,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxyurea11$288
Amlodipine Besylate11$55

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in West New York

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →